Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings

Authors

Document Type

Letter to the Editor

Publication Date

2-21-2026

Journal

The American journal of medicine

DOI

10.1016/j.amjmed.2026.01.035

Department

Medicine

Share

COinS